Peng Lishan, Zhong Wenzhao
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
Zhongguo Fei Ai Za Zhi. 2024 Sep 20;27(9):704-710. doi: 10.3779/j.issn.1009-3419.2024.102.32.
Non-small cell lung cancer (NSCLC) is one of the most prevalent and deadliest cancers worldwide. While the use of targeted therapies and immunotherapies in precision medicine has improved outcomes for some patients, a significant portion of individuals still fail to benefit, emphasizing the need to investigate the underlying mechanisms of resistance. Survival analyses have shown that NSCLC patients with SMARCA4 mutations often have poor prognoses. SMARCA4, the core ATPase subunit of the SWI/SNF chromatin remodeling complex, plays a critical role in regulating gene transcription by modifying chromatin accessibility. This influences essential cellular processes such as differentiation and cell cycle regulation, and SMARCA4 is widely regarded as a tumor suppressor. This review will explore the role of SMARCA4 mutations in tumor progression, its clinicopathological features in NSCLC, its impact on treatment outcomes, and potential therapeutic strategies. .
非小细胞肺癌（NSCLC）是全球最常见、最致命的癌症之一。虽然精准医学中靶向治疗和免疫治疗的应用改善了部分患者的治疗效果，但仍有很大一部分患者未能从中获益，这凸显了研究耐药潜在机制的必要性。生存分析表明，携带SMARCA4突变的NSCLC患者预后往往较差。SMARCA4是SWI/SNF染色质重塑复合体的核心ATP酶亚基，通过改变染色质可及性在调节基因转录中起关键作用。这影响了诸如分化和细胞周期调控等重要细胞过程，SMARCA4被广泛认为是一种肿瘤抑制因子。本综述将探讨SMARCA4突变在肿瘤进展中的作用、其在NSCLC中的临床病理特征、对治疗结果的影响以及潜在的治疗策略。
